Stifel and JMP Securities to be joint bookrunning managers for deal
By Devika Patel
Knoxville, Tenn., July 31 – Marinus Pharmaceuticals, Inc. said it priced its $45 million initial public sale of stock with a $6.75 million greenshoe. The deal was announced May 12.
The company will sell 5,625,000 common shares at $8.00 apiece.
Stifel, Nicolaus & Co. and JMP Securities LLC are the joint bookrunning managers.
Settlement is expected Aug. 5.
Proceeds will be used for clinical trials, working capital and general corporate purposes.
The biopharmaceutical company is based in New Haven, Conn. The company intends to list its common stock on the Nasdaq under the symbol “MRNS.”
| Issuer: | Marinus Pharmaceuticals, Inc.
|
| Issue: | Common stock
|
| Amount: | $45 million
|
| Greenshoe: | $6.75 million
|
| Shares: | 5,625,000
|
| Price: | $8.00
|
| Warrants: | No
|
| Bookrunners: | Stifel, Nicolaus & Co. and JMP Securities LLC
|
| Lead manager: | Oppenheimer & Co.
|
| Co-manager: | Janney Montgomery Scott
|
| Announcement date: | May 12
|
| Pricing date: | July 31
|
| Settlement date: | Aug. 5
|
| Stock exchange: | Nasdaq: MRNS
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
